A phase II trial assessing CA-002
Latest Information Update: 24 Jan 2024
At a glance
- Drugs CA 002 (Primary)
- Indications Peanut hypersensitivity
- Focus Therapeutic Use
Most Recent Events
- 24 Jan 2024 New trial record
Latest Information Update: 24 Jan 2024